Effectiveness of BA.1-and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

被引：13

作者：

Arashiro, Takeshi ^{[1
,2
,3
,4
]}

Arima, Yuzo ^{[1
]}

Kuramochi, Jin ^{[5
,6
]}

Muraoka, Hirokazu ^{[7
]}

Sato, Akihiro ^{[8
]}

Chubachi, Kumi ^{[9
]}

Yanai, Atsushi ^{[10
]}

Arioka, Hiroko ^{[10
]}

Uehara, Yuki ^{[11
,12
]}

Ihara, Genei ^{[13
]}

Kato, Yasuyuki ^{[14
]}

Yanagisawa, Naoki ^{[15
]}

Ueda, Akihiro ^{[16
]}

Kato, Hideaki ^{[17
]}

Oka, Hideaki ^{[18
]}

Nishida, Yusuke ^{[18
]}

Nidaira, Yuki ^{[5
]}

Asami, Takahiro ^{[19
]}

Jinta, Torahiko ^{[20
]}

Nakamura, Akira ^{[21
]}

Oba, Kunihiro ^{[22
]}

Taniyama, Daisuke ^{[23
]}

Yamamoto, Kei ^{[18
]}

Tanaka, Katsushi ^{[17
]}

Ueshima, Kankuro ^{[24
]}

Fuwa, Tetsuji ^{[24
]}

Stucky, Ashley ^{[1
]}

Suzuki, Tadaki ^{[2
]}

Smith, Chris ^{[3
]}

Hibberd, Martin ^{[3
]}

Ariyoshi, Koya ^{[4
]}

Suzuki, Motoi ^{[1
]}

机构：

[1] Natl Inst Infect Dis, Ctr Surveillance Immunizat & Epidemiol Res, Tokyo, Japan

[2] Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan

[3] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England

[4] Nagasaki Univ, Sch Trop Med & Global Hlth, Nagasaki, Japan

[5] Kuramochi Clin Interpk, Tochigi, Japan

[6] Tokyo Med & Dent Univ, Dept Global Hlth Promot, Tokyo, Japan

[7] Clin TAMACHI, Tokyo, Japan

[8] KARADA Internal Med Clin, Tokyo, Japan

[9] Chubachi Internal Resp Med Clin, Tokyo, Japan

[10] St Lukes Int Hosp, Dept Gen Internal Med, Tokyo, Japan

[11] St Lukes Int Hosp, Dept Clin Lab, Tokyo, Japan

[12] Fujita Hlth Univ, Sch Med, Dept Infect Dis, Aichi, Japan

[13] Machida Ekimae Naika Clin, Tokyo, Japan

[14] Int Univ Hlth, Welf Narita Hosp, Dept Infect Dis, Chiba, Japan

[15] Yanagisawa Clin, Tokyo, Japan

[16] Japanese Red Cross Med Ctr, Dept Infect Dis, Tokyo, Japan

[17] Yokohama City Univ Med, Infect Prevent & Control Dept, Yokohama, Japan

[18] Saitama Med Ctr, Dept Gen Internal Med & Infect Dis, Saitama, Japan

[19] Sano Kosei Gen Hosp, Dept Internal Med, Tochigi, Japan

[20] St Lukes Int Hosp, Dept Pulm Med, Tokyo, Japan

[21] Asahi Gen Hosp, Dept Internal Med, Chiba, Japan

[22] Showa Gen Hosp, Dept Pediat, Tokyo, Japan

[23] Showa Gen Hosp, Dept Infect Dis, Tokyo, Japan

[24] NATURALI Co Ltd, Tokyo, Japan

来源：

OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 06期

关键词：

COVID-19; SARS-CoV-2; variants; test-negative design; vaccine effectiveness;

D O I：

10.1093/ofid/ofad240

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined). In this multi-center study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent vaccines against symptomatic infection during the BA.5-dominant period was high compared to no vaccination (65%/76%) and moderate compared to monovalent vaccines >6 months before (46% combined).

引用

页数：6

共 50 条

[31] Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) [J].

Maeda, Haruka ;

Saito, Nobuo ;

Igarashi, Ataru ;

Ishida, Masayuki ;

Terada, Mayumi ;

Masuda, Shingo ;

Osawa, Ryosuke ;

Hosokawa, Naoto ;

Nakashima, Kei ;

Kamura, Hiroshi ;

Imura, Haruki ;

Inoue, Hiroki ;

Matsuzaka, Suguru ;

Sugimoto, Yukihiro ;

Kuwamitsu, Osamu ;

Motohashi, Iori ;

Morikawa, Toru ;

Oda, Rentaro ;

Hoshina, Yuiko ;

Matono, Takashi ;

Teshigahara, Osamu ;

Sando, Eiichiro ;

Asami, Sadaharu ;

Kudo, Satoshi ;

Akizuki, Noboru ;

Muto, Yoshikazu ;

Hayakawa, Tomoichiro ;

Kishaba, Tomoo ;

Ohara, Yasuji ;

Kubo, Yoshinao ;

Suzuki, Motoi ;

Morimoto, Konosuke .

EXPERT REVIEW OF VACCINES, 2024, 23 (01) :213-225

[32] Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination [J].

Lapointe, Hope R. R. ;

Mwimanzi, Francis ;

Cheung, Peter K. K. ;

Sang, Yurou ;

Yaseen, Fatima ;

Kalikawe, Rebecca ;

Datwani, Sneha ;

Waterworth, Rachel ;

Umviligihozo, Gisele ;

Ennis, Siobhan ;

Young, Landon ;

Dong, Winnie ;

Kirkby, Don ;

Burns, Laura ;

Leung, Victor ;

Holmes, Daniel T. T. ;

DeMarco, Mari L. L. ;

Simons, Janet ;

Matic, Nancy ;

Montaner, Julio S. G. ;

Brumme, Chanson J. J. ;

Prystajecky, Natalie ;

Niikura, Masahiro ;

Lowe, Christopher F. F. ;

Romney, Marc G. G. ;

Brockman, Mark A. A. ;

Brumme, Zabrina L. L. .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[33] Risk Factors Related to COVID-19 Reinfection and Fatality During the Omicron (BA.1/BA. 2) Period in Korea [J].

Lee, Ju Hee ;

Hwang, Ji Hae ;

Jang, Eun Jung ;

Kim, Ryu Kyung ;

Lee, Kil Hun ;

Park, Seon Kyeong ;

Gwack, Jin ;

Park, Young Joon .

JOURNAL OF KOREAN MEDICAL SCIENCE, 2023, 38 (34)

[34] Comparing COVID-19 severity in patients hospitalized for community-associated Delta, BA.1 and BA.4/5 variant infection [J].

Socan, Maja ;

Mrzel, Maja ;

Prosenc, Katarina ;

Korva, Misa ;

Avsic-Zupanc, Tatjana ;

Poljak, Mario ;

Lunar, Maja M. ;

Zupanic, Tina .

FRONTIERS IN PUBLIC HEALTH, 2024, 12

[35] Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study [J].

He, Xiaofeng ;

Zeng, Biao ;

Wang, Ye ;

Pang, Yulian ;

Zhang, Meng ;

Hu, Ting ;

Liang, Yuanhao ;

Kang, Min ;

Tang, Shixing .

FRONTIERS IN IMMUNOLOGY, 2023, 14

[36] Effectiveness of BNT162b2 BA.4/5 Bivalent mRNA Vaccine Against Symptomatic COVID-19 Among Immunocompetent Individuals Testing at a Large US Retail Pharmacy [J].

Rudolph, Abby E. ;

Khan, Farid L. ;

Shah, Amy ;

Singh, Tanya G. ;

Wiemken, Timothy L. ;

Puzniak, Laura A. ;

Jodar, Luis ;

McLaughlin, John M. .

JOURNAL OF INFECTIOUS DISEASES, 2024, 229 (03) :648-659

[37] Seroepidemiology of SARS-CoV-2 Virus in Healthcare Workers before Circulation of the Omicron Sublineages BA.4/BA.5 in Vojvodina, Serbia [J].

Ristic, Mioljub ;

Vukovic, Vladimir ;

Patic, Aleksandra ;

Markovic, Milos ;

Petrovic, Vladimir .

VACCINES, 2022, 10 (12)

[38] Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022-2023 Winter Season [J].

Moss, Stephen ;

Jurkowicz, Menucha ;

Nemet, Ital ;

Atari, Nofar ;

Kliker, Limor ;

Abd-Elkader, Bayan ;

Gonen, Tal ;

Martin, Emily Toth ;

Lustig, Yaniv ;

Regev-Yochay, Gili ;

Mandelboim, Michal .

VACCINES, 2023, 11 (10)

[39] Effectiveness of BNT162b2 BA.4/5 Bivalent COVID-19 Vaccine against Long COVID Symptoms: A US Nationwide Study [J].

Di Fusco, Manuela ;

Sun, Xiaowu ;

Allen, Kristen E. ;

Yehoshua, Alon ;

Berk, Alexandra ;

Alvarez, Mary B. ;

Porter, Thomas M. ;

Ren, Jinma ;

Puzniak, Laura ;

Lopez, Santiago M. C. ;

Cappelleri, Joseph C. .

VACCINES, 2024, 12 (02)

[40] Antibody responses in blood and saliva post COVID-19 bivalent booster do not reveal an Omicron BA.4/BA.5-specific response [J].

Baker Jr, Ryan ;

Lawlor, Rebecca ;

Smith, Maeve ;

Price, Jessica ;

Eaton, Ashley ;

Lover, Andrew ;

Alfandari, Dominique ;

Reinhart, Peter ;

Arcaro, Kathleen F. ;

Osborne, Barbara A. .

FRONTIERS IN IMMUNOLOGY, 2024, 15

← 1 2 3 4 5 →